A 2-part, randomized, double-blind, placebo-controlled, multiple-rising dose study to evaluate the safety, tolerability, and pharmacokinetics of MK3281 in healthy male subjects and safety, tolerability, pharmacokinetics and pharmacodynamics of MK3281 in hepatitis C infected male patients.

Trial Profile

A 2-part, randomized, double-blind, placebo-controlled, multiple-rising dose study to evaluate the safety, tolerability, and pharmacokinetics of MK3281 in healthy male subjects and safety, tolerability, pharmacokinetics and pharmacodynamics of MK3281 in hepatitis C infected male patients.

Completed
Phase of Trial: Phase I

Latest Information Update: 31 Mar 2017

At a glance

  • Drugs MK 3281 (Primary)
  • Indications Hepatitis C
  • Focus Adverse reactions
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 18 Oct 2016 Status changed from discontinued to completed.
    • 05 Jan 2012 Planned end date changed from 1 Dec 2009 to 1 Nov 2009 as reported by ClinicalTrials.gov.
    • 12 Feb 2010 Actual patient number (60) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top